Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh acquired 2,383,333 shares of Scribe Therapeutics stock in a transaction on Friday, July 24th. The shares were bought at an average cost of $15.15 per share, for a total transaction of $36,107,494.95. Following the completion of the purchase, the director directly owned 3,080,983 shares of the company’s stock, valued at $46,676,892.45. The trade was a 341.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Behzad Aghazadeh also recently made the following trade(s):
- On Tuesday, July 28th, Behzad Aghazadeh acquired 7,905 shares of Scribe Therapeutics stock. The shares were bought at an average price of $18.25 per share, for a total transaction of $144,266.25.
Scribe Therapeutics Price Performance
Shares of NASDAQ SCTX traded down $0.91 during trading hours on Tuesday, hitting $18.06. 428,502 shares of the company traded hands, compared to its average volume of 423,801. Scribe Therapeutics Inc. has a 12 month low of $17.31 and a 12 month high of $25.49.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
